{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:19:41Z","timestamp":1790734781124,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Hypertension has a high prevalence in heart failure with preserved ejection fraction (HFpEF), which can be controlled, uncontrolled, or even resistant. The effects of empagliflozin on systolic blood pressure (SBP), time in target range, incidence of hypertensive urgencies, and studied cardiovascular and renal outcomes in different hypertension categories and after treatment with empagliflozin in the EMPEROR-Preserved trial were explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 5533 patients were studied and the population was separated into resistant (resHTN), uncontrolled (uctrHTN), and controlled (ctrHTN) hypertension. The effect of SBP on outcomes and treatment effects of empagliflozin were explored. Analyses were done with Cox regression analyses adjusted for demographic and clinical confounders and with a mixed model for repeated measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Empagliflozin reduced SBP in resHTN slightly more than in the other categories in the first weeks, while thereafter there were no significant differences. The modest reduction in SBP resulted in a moderate increase in time at target and reduced hypertensive urgencies. The primary endpoint was more prevalent in resHTN (P = .0358), but the treatment effect of empagliflozin on the primary endpoint was similar in resHTN, uctrHTN, and ctrHTN (P for interaction = .92) as was the improvement of the estimated glomerular filtration rate slope (P for interaction = .95) and change in quality of life by empagliflozin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In HFpEF, the prevalence of resHTN is high and is associated with frequently higher outcome rates compared with ctrHTN and uctrHTN. The treatment effect was not modified by hypertension categories. This indicates that in HFpEF, moderate modifications of blood pressure do not affect overall outcomes and treatment effects of empagliflozin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehae938","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T07:19:11Z","timestamp":1740640751000},"source":"Crossref","is-referenced-by-count":19,"title":["Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2976-2514","authenticated-orcid":false,"given":"Michael","family":"B\u00f6hm","sequence":"first","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4tsklinikum des Saarlandes, Saarland University , Kirrberger Str.1, Homburg\/Saar 66421 ,","place":["Germany"]},{"name":"Cape Heart Institute , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Research Institute , Dallas, TX ,","place":["USA"]},{"name":"Department of Medicine, University of Mississippi , Jackson, MS ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Coats","sequence":"additional","affiliation":[{"name":"Heart Research Institute , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1434-9556","authenticated-orcid":false,"given":"Lucas","family":"Lauder","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4tsklinikum des Saarlandes, Saarland University , Kirrberger Str.1, Homburg\/Saar 66421 ,","place":["Germany"]},{"name":"Cape Heart Institute , Cape Town ,","place":["South Africa"]},{"name":"Department of Cardiology, University Heart Center, University Hospital Basel , Basel ,","place":["Switzerland"]},{"name":"Cardiovascular Research Institute Basel (CRIB), University Heart Center, University Hospital Basel , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-549X","authenticated-orcid":false,"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4tsklinikum des Saarlandes, Saarland University , Kirrberger Str.1, Homburg\/Saar 66421 ,","place":["Germany"]},{"name":"Cape Heart Institute , Cape Town ,","place":["South Africa"]},{"name":"Department of Cardiology, University Heart Center, University Hospital Basel , Basel ,","place":["Switzerland"]},{"name":"Cardiovascular Research Institute Basel (CRIB), University Heart Center, University Hospital Basel , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"School of Medicine, National and Kapodistrian University of Athens, Athens University Hospital Attikon , 1 Rimini St, Athens 12462 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Centre d'Investigation Clinique- Plurith\u00e9matique Inserm CIC-P 1433, Universit\u00e9 de Lorraine , Nancy ,","place":["France"]},{"name":"Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy ,","place":["France"]},{"name":"Cardiovascular R&D Centre\u2014UnIC@RISE, Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto , Porto ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J","family":"Pocock","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene & Tropical Medicine , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Brueckmann","sequence":"additional","affiliation":[{"name":"Therapeutic Area of Cardiorenal and Metabolic Medicine, Boehringer Ingelheim International , Binger Str. 173, Ingelheim 55218 ,","place":["Germany"]},{"name":"First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg , Mannheim ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle J","family":"Hauske","sequence":"additional","affiliation":[{"name":"Therapeutic Area of Cardiorenal and Metabolic Medicine, Boehringer Ingelheim International , Binger Str. 173, Ingelheim 55218 ,","place":["Germany"]},{"name":"Fifth Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg , Mannheim ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5955-8303","authenticated-orcid":false,"given":"Elke","family":"Schueler","sequence":"additional","affiliation":[{"name":"mainanalytics GmbH, Sulzbach , Otto-Volger-Str. 3c, Sulzbach\/Taunus 65843 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-5301","authenticated-orcid":false,"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Epidemiology, Comprehensive Heart Failure Center (CHFC) , Am Schwarzenberg 15, W\u00fcrzburg 97078 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-8533","authenticated-orcid":false,"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, St Michael\u2019s Hospital , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Surgery, University of Toronto , Toronto, Ontario , M5T 1P5","place":["Canada"]},{"name":"Department Pharmacology and Toxicology, University of Toronto , Toronto, Ontario , M5G 2C8","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Institut Lorrain du Coeur et des Vaisseaux , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1828-2387","authenticated-orcid":false,"given":"Milton","family":"Packer","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Science, Baylor University Medical Center , 3500 Gaston Ave, Dallas, TX 75246 ,","place":["USA"]},{"name":"Faculty of Medicine, National Heart and Lung Institute, Imperial College , Exhibition Road, London SW7 2AZ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0805-8683","authenticated-orcid":false,"given":"Stefan D","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK) of German Heart Center Charit\u00e9 , Berlin ,","place":["Germany"]},{"name":"German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9 Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"2025032500030808400_ehae938-B1","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease study 2019","volume":"396","author":"GBD 2019 Risk Factors Collaborators","year":"2020","journal-title":"Lancet"},{"key":"2025032500030808400_ehae938-B2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","article-title":"The transition from hypertension to heart failure: contemporary update","volume":"5","author":"Messerli","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2025032500030808400_ehae938-B3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ejheart.2007.12.010","article-title":"Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial","volume":"10","author":"McMurray","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2025032500030808400_ehae938-B4","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ejhf.2894","article-title":"Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension","volume":"25","author":"Anker","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2025032500030808400_ehae938-B5","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1097\/HJH.0000000000002910","article-title":"Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension","volume":"39","author":"Kasiakogias","year":"2021","journal-title":"J Hypertens"},{"key":"2025032500030808400_ehae938-B6","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2025032500030808400_ehae938-B7","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2025032500030808400_ehae938-B8","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","article-title":"The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019)","volume":"42","author":"Umemura","year":"2019","journal-title":"Hypertens Res"},{"key":"2025032500030808400_ehae938-B9","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"38","author":"Unger","year":"2020","journal-title":"J Hypertens"},{"key":"2025032500030808400_ehae938-B10","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1111\/jch.14269","article-title":"Resistance to antihypertensive treatment and long-term risk: the atherosclerosis risk in communities study","volume":"23","author":"Wijkman","year":"2021","journal-title":"J Clin Hypertens"},{"key":"2025032500030808400_ehae938-B11","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/HYPERTENSIONAHA.121.18198","article-title":"Cardiovascular prognosis in drug-resistant hypertension stratified by 24-hour ambulatory blood pressure: the JAMP study","volume":"78","author":"Kario","year":"2021","journal-title":"Hypertension"},{"key":"2025032500030808400_ehae938-B12","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1093\/eurjpc\/zwad066","article-title":"Apparent treatment-resistant hypertension associated lifetime cardiovascular risk in a longitudinal national registry","volume":"30","author":"Ebinger","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2025032500030808400_ehae938-B13","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2025032500030808400_ehae938-B14","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2025032500030808400_ehae938-B15","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jchf.2022.04.006","article-title":"Apparent treatment-resistant hypertension across the spectrum of heart failure phenotypes in the Swedish HF registry","volume":"10","author":"Jackson","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2025032500030808400_ehae938-B16","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1002\/ejhf.2064","article-title":"Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial","volume":"22","author":"Anker","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2025032500030808400_ehae938-B17","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2025032500030808400_ehae938-B18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/jch.13550","article-title":"Incidence, prevalence, and predictors of treatment-resistant hypertension with intensive blood pressure lowering","volume":"21","author":"Smith","year":"2019","journal-title":"J Clin Hypertens"},{"key":"2025032500030808400_ehae938-B19","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.jchf.2017.09.010","article-title":"Blood pressure risk associations in heart failure: true effects or inverse causality?","volume":"5","author":"B\u00f6hm","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2025032500030808400_ehae938-B20","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/eurheartj\/ehac693","article-title":"Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial","volume":"44","author":"B\u00f6hm","year":"2023","journal-title":"Eur Heart J"},{"key":"2025032500030808400_ehae938-B21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jchf.2022.09.002","article-title":"Blood pressure and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: DELIVER","volume":"11","author":"Selvaraj","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2025032500030808400_ehae938-B22","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","article-title":"Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF","volume":"38","author":"B\u00f6hm","year":"2017","journal-title":"Eur Heart J"},{"key":"2025032500030808400_ehae938-B23","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.jacc.2020.02.009","article-title":"Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril\/valsartan","volume":"75","author":"Selvaraj","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025032500030808400_ehae938-B24","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jacc.2021.07.049","article-title":"Empagliflozin improves cardiovascular and renal outcomes in heart failure irrespective of systolic blood pressure","volume":"78","author":"B\u00f6hm","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025032500030808400_ehae938-B25","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jchf.2017.08.015","article-title":"Reverse J-curve relationship between on-treatment blood pressure and mortality in patients with heart failure","volume":"5","author":"Lee","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2025032500030808400_ehae938-B26","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025032500030808400_ehae938-B27","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.123.065254","article-title":"Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial","volume":"148","author":"Ostrominski","year":"2023","journal-title":"Circulation"},{"key":"2025032500030808400_ehae938-B28","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1097\/HJH.0000000000002492","article-title":"Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME","volume":"38","author":"B\u00f6hm","year":"2020","journal-title":"J Hypertens"},{"key":"2025032500030808400_ehae938-B29","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1093\/eurheartj\/ehaa496","article-title":"Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)","volume":"41","author":"Serenelli","year":"2020","journal-title":"Eur Heart J"},{"key":"2025032500030808400_ehae938-B30","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jacc.2021.01.014","article-title":"Systolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension","volume":"77","author":"Fatani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025032500030808400_ehae938-B31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1161\/HYPERTENSIONAHA.122.20141","article-title":"Systolic blood pressure time in target range and major adverse kidney and cardiovascular events","volume":"80","author":"Buckley","year":"2023","journal-title":"Hypertension"},{"key":"2025032500030808400_ehae938-B32","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/jch.13083","article-title":"Hospital and out-of-hospital mortality in 670 hypertensive emergencies and urgencies","volume":"19","author":"Guiga","year":"2017","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2025032500030808400_ehae938-B33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1146\/annurev-med-050922-052605","article-title":"Management of resistant hypertension","volume":"75","author":"Lauder","year":"2024","journal-title":"Annu Rev Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehae938\/62263272\/ehae938.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehae938\/62263272\/ehae938.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T01:06:43Z","timestamp":1743210403000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehae938\/8051580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":33,"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehae938","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"article-number":"ehae938"}}